{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:17:32Z","timestamp":1791821852138,"version":"4.3.4"},"reference-count":176,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Naval Medical University","award":["2024MS001"],"award-info":[{"award-number":["2024MS001"]}]},{"award":["2024MS001"],"award-info":[{"award-number":["2024MS001"]}],"id":[{"id":"https:\/\/ror.org\/04k21pf91","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) represent a paradigm shift in precision oncology, ingeniously coupling the targeting capability of monoclonal antibodies with the lethal potency of cytotoxic payloads to selectively eradicate tumor cells. While ADCs have demonstrated transformative efficacy across a spectrum of malignancies, the emergence of intrinsic and acquired resistance remains a formidable obstacle, frequently culminating in treatment failure and disease progression. The landscape of ADC resistance is highly complex, governed by a diverse array of molecular mechanisms. These range from alterations in antigen dynamics\u2014such as downregulation or impaired trafficking\u2014to intracellular adaptations, including the upregulation of multi-drug resistance efflux pumps, enhanced DNA damage repair capacity, and the blockade of apoptotic cell death. Moreover, tumor cells often exploit compensatory signaling networks to bypass therapeutic inhibition. Consequently, elucidating the intricate signaling cascades that drive these resistance phenotypes is critical for clinical advancement. This review comprehensively examines the pivotal signaling pathways underpinning ADC resistance and evaluates novel therapeutic strategies designed to circumvent these molecular barriers, aiming to optimize patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms27073287","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:06:21Z","timestamp":1775441181000},"page":"3287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antibody\u2013Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives"],"prefix":"10.3390","volume":"27","author":[{"given":"Dan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Student Team, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2387-4572","authenticated-orcid":false,"given":"Jiaping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-5895","authenticated-orcid":false,"given":"Lianghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9185-4024","authenticated-orcid":false,"given":"Mingjuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2230618","DOI":"10.1080\/19420862.2023.2230618","article-title":"Therapeutic index improvement of antibody-drug conjugates","volume":"15","author":"Gerber","year":"2023","journal-title":"mAbs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","article-title":"Antibody drug conjugates as targeted cancer therapy: Past development, present challenges and future opportunities","volume":"46","author":"Maiti","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.21037\/tlcr-24-964","article-title":"The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: A narrative review","volume":"13","author":"Zhou","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: Fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_6","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_7","first-page":"5","article-title":"Brentuximab vedotin in T-cell lymphoma","volume":"12","author":"Dickinson","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","article-title":"Trastuzumab Emtansine: First Global Approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s40265-020-01408-7","article-title":"Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer","volume":"80","year":"2020","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.18632\/oncotarget.28701","article-title":"Signaling pathway dysregulation in breast cancer","volume":"16","author":"Ryspayeva","year":"2025","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.molmed.2025.08.001","article-title":"Targeting pathological ERK1\/2 signaling in cancer and beyond","volume":"32","author":"Schanbacher","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e35989","DOI":"10.1016\/j.heliyon.2024.e35989","article-title":"Blocking the WNT\/\u03b2-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","article-title":"Wnt\/\u03b2-catenin mediated signaling pathways in cancer: Recent advances, and applications in cancer therapy","volume":"24","author":"Wu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104436","DOI":"10.1016\/j.drudis.2025.104436","article-title":"ErbB\/HER family in cancer immunology: Therapeutic advances and mechanisms","volume":"30","author":"Yin","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-20-4465","article-title":"Thirty Years of HER3: From Basic Biology to Therapeutic Interventions","volume":"27","author":"Haikala","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, J.X., Shan, K., Huang, W., Su, Q., Qi, Y.J., Zhang, Z.H., Zhu, J.Q., and Du, E. (2025). The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1432586"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1051\/vcm\/2024007","article-title":"Updates on altered signaling pathways in tumor drug resistance","volume":"5","author":"Li","year":"2024","journal-title":"Vis. Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody\u2013Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody\u2013drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity","volume":"77","author":"Arribas","year":"2017","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Li, H.Y., Prever, L., Hirsch, E., and Gulluni, F. (2021). Targeting PI3K\/AKT\/mTOR Signaling Pathway in Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13143517"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pungsrinont, T., Kallenbach, J., and Baniahmad, A. (2021). Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011088"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S.R., Manzella, L., and Vigneri, P. (2021). AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.662232"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-021-01137-8","article-title":"Targeting Akt in cancer for precision therapy","volume":"14","author":"Hua","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"173983","DOI":"10.1016\/j.ejphar.2021.173983","article-title":"The PI3K\/Akt\/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions","volume":"898","author":"Pirsalehi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Guerini Rocco, E., Criscitiello, C., Malapelle, U., and Invernizzi, M. (2020). PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 11.","DOI":"10.3390\/genes11070719"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ajpath.2018.11.013","article-title":"Mammalian Target of Rapamycin","volume":"189","author":"Wipperman","year":"2019","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41589-021-00813-7","article-title":"Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth","volume":"17","author":"Lee","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.kint.2020.07.052","article-title":"How mTORC1 makes sense of nutrients","volume":"99","author":"Luciani","year":"2021","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"Kim","year":"2016","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony","volume":"285","author":"Foster","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_44","first-page":"59","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancer therapy: Molecular basis and therapeutic strategies","volume":"8","author":"Hao","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4792-0","article-title":"Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy","volume":"171","author":"Jain","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3390\/cancers6031441","article-title":"The Role of PI3K\/Akt\/mTOR Signaling in Gastric Carcinoma","volume":"6","author":"Matsuoka","year":"2014","journal-title":"Cancers"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2174\/0115665240309647240516042716","article-title":"Emerging Insights into the PI3K\/AKT\/mTOR Signaling Pathway and Non-Coding RNA-mediated Drug Resistance in Glioblastoma","volume":"25","author":"Shimia","year":"2025","journal-title":"Curr. Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Hormone-Positive Breast Cancer","volume":"80","author":"Nunnery","year":"2020","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-012-2043-3","article-title":"Overcoming acquired resistance to anticancer therapy: Focus on the PI3K\/AKT\/mTOR pathway","volume":"71","author":"Burris","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer","volume":"68","author":"Lluch","year":"2008","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I\u2014Activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1479-5876-11-180","article-title":"Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF\/MEK inhibition and is abrogated by anti-ErbB3 antibodies","volume":"11","author":"Fattore","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"115648","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41467-020-15979-2","article-title":"Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy","volume":"11","author":"Baumann","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1021\/acs.jproteome.1c00550","article-title":"Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition","volume":"20","author":"Wang","year":"2021","journal-title":"J. Proteome Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: Therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41419-020-03241-y","article-title":"Autocrine IL-6\/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma","volume":"11","author":"Sreenivasan","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sreenivasan, L., Li, L.V., Leclair, P., and Lim, C.J. (2022). Targeting the gp130\/STAT3 Axis Attenuates Tumor Microenvironment Mediated Chemoresistance in Group 3 Medulloblastoma Cells. Cells, 11.","DOI":"10.3390\/cells11030381"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Roth, J.S., Guo, H., Chen, L., Shen, M., Gbadegesin, O., Robey, R.W., Gottesman, M.M., and Hall, M.D. (2025). Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters. bioRxiv.","DOI":"10.1101\/2025.05.22.651305"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/ijo.2022.5375","article-title":"Curcumin inhibits the cancer-associated fibroblast-derived chemoresistance of gastric cancer through the suppression of the JAK\/STAT3 signaling pathway","volume":"61","author":"Ham","year":"2022","journal-title":"Int. J. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1158\/0008-5472.CAN-12-2353","article-title":"Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma","volume":"73","author":"Ara","year":"2013","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.7150\/thno.29146","article-title":"Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases","volume":"9","author":"Yap","year":"2019","journal-title":"Theranostics"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Patel, S., Alam, A., Pant, R., and Chattopadhyay, S. (2019). Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02872"},{"key":"ref_67","first-page":"305","article-title":"The Wnt\/\u03b2-catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma","volume":"19","author":"Wang","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3892\/or.2014.3351","article-title":"Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer","volume":"32","author":"Li","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12195-018-0542-y","article-title":"Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition","volume":"11","author":"Claas","year":"2018","journal-title":"Cell Mol. Bioeng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"936","DOI":"10.21037\/tlcr-24-100","article-title":"Antibody-drug conjugate development: Opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?","volume":"13","author":"Hida","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"58771","DOI":"10.18632\/oncotarget.17680","article-title":"Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement","volume":"8","author":"Choi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1541-7786.MCR-13-0042","article-title":"MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance","volume":"11","author":"Paulson","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/bcr3480","article-title":"An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models","volume":"15","author":"Xia","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-16-0123","article-title":"JNK Pathway Activation Modulates Acquired Resistance to EGFR\/HER2\u2013Targeted Therapies","volume":"76","author":"Manole","year":"2016","journal-title":"Cancer Res."},{"key":"ref_75","first-page":"153","article-title":"Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions","volume":"22","author":"Pearson","year":"2001","journal-title":"Endocr. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1126\/science.8503013","article-title":"Complexes of Ras GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase","volume":"260","author":"Moodie","year":"1993","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/358417a0","article-title":"Raf-1 activates MAP kinase-kinase","volume":"358","author":"Kyriakis","year":"1992","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Chen, C.B., Nelson, L.J., Avila, M.A., and Cubero, F.J. (2019). Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells, 8.","DOI":"10.3390\/cells8101172"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1101\/gad.1107303","article-title":"Mechanism of p38 MAP kinase activation in vivo","volume":"17","author":"Brancho","year":"2003","journal-title":"Genes Dev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.humpath.2012.11.006","article-title":"Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions","volume":"44","author":"Voss","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: A master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/eci.12441","article-title":"The Ras\/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications","volume":"45","author":"Delire","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Dimri, M., and Satyanarayana, A. (2020). Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12020491"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/138161213804547187","article-title":"Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway","volume":"19","author":"Cossa","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.celrep.2013.08.023","article-title":"Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma","volume":"4","author":"Villanueva","year":"2013","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.bcp.2006.04.013","article-title":"Jaks and cytokine receptors\u2014An intimate relationship","volume":"72","author":"Haan","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tig.2003.11.003","article-title":"Acquiring signalling specificity from the cytokine receptor gp130","volume":"20","author":"Ernst","year":"2004","journal-title":"Trends Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an Oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: New and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","article-title":"Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells","volume":"10","author":"Wang","year":"2003","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e23828","DOI":"10.4161\/jkst.23828","article-title":"Targeting the tumor microenvironment","volume":"2","author":"Bournazou","year":"2014","journal-title":"JAK-STAT"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT Pathway at Twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1182\/blood-2024-206382","article-title":"Inhibition of p300\/CBP Overcomes BTK Inhibitor Resistance in MCL By Counteracting IL-6\/JAK\/STAT3 Signaling","volume":"144","author":"Tashiro","year":"2024","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Xu, J.Y., Zhang, J.R., Mao, Q.F., Wu, J., and Wang, Y. (2022). The Interaction Between Autophagy and JAK\/STAT3 Signaling Pathway in Tumors. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.880359"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1593\/neo.13706","article-title":"The IL-6\/JAK\/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis","volume":"15","author":"Chang","year":"2013","journal-title":"Neoplasia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"150348","DOI":"10.1016\/j.bbrc.2024.150348","article-title":"Role of Wnt\/\u03b2-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors","volume":"729","author":"Samant","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-Catenin Signaling, Disease, and Emerging Therapeutic Modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-Catenin Signaling and Disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: Function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.molcel.2015.03.015","article-title":"Dishevelled Promotes Wnt Receptor Degradation through Recruitment of ZNRF3\/RNF43 E3 Ubiquitin Ligases","volume":"58","author":"Jiang","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1242\/dev.013540","article-title":"Initiation of Wnt signaling: Control of Wnt coreceptor Lrp6 phosphorylation\/activation via frizzled, dishevelled and axin functions","volume":"135","author":"Zeng","year":"2008","journal-title":"Development"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.cellsig.2009.11.021","article-title":"Dishevelled: The hub of Wnt signaling","volume":"22","author":"Gao","year":"2010","journal-title":"Cell Signal."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00018-010-0329-3","article-title":"Regulation of Lrp6 phosphorylation","volume":"67","author":"Niehrs","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.molcel.2016.08.026","article-title":"Wnt Signalosome Assembly by DEP Domain Swapping of Dishevelled","volume":"64","author":"Gammons","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3892\/mmr.2020.11744","article-title":"Wnt\/\u03b2-catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review)","volume":"23","author":"Zhu","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1002\/mco2.446","article-title":"Receptor tyrosine kinases: Biological functions and anticancer targeted therapy","volume":"4","author":"Zhang","year":"2023","journal-title":"MedComm"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lee, J.C., Vivanco, I., Beroukhim, R., Huang, J.H.Y., Feng, W.L., DeBiasi, R.M., Yoshimoto, K., King, J.C., Nghiemphu, P., and Yuza, Y. (2006). Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030485"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.molcel.2021.05.029","article-title":"Oncogenic signaling of RTK fusions becomes more granular","volume":"81","author":"Cuneo","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Jiang, Z.Y., Gu, Z.H., Yu, X.M., Cheng, T., and Liu, B.F. (2024). Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1447678"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1758835920920069","DOI":"10.1177\/1758835920920069","article-title":"Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: Antibody-drug conjugates as lead drug candidates for clinical trials","volume":"12","author":"Yao","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1538-7445.AM2025-1287","article-title":"Clinical relevance and translatability of NSCLC patient-derived xenograft (PDX) models for evaluating cMET-targeted therapies","volume":"85","author":"Leger","year":"2025","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1158\/1538-7445.AM2025-6851","article-title":"An integrated preclinical platform for antibody-drug conjugate development","volume":"85","author":"Cairo","year":"2025","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1158\/1538-7445.AM2025-2691","article-title":"Configurable multiplex immunofluorescence panels for emerging ADC targets","volume":"85","author":"Cajigas","year":"2025","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1158\/1538-7445.AM2024-2118","article-title":"SGN-CEACAM5C\/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models","volume":"84","author":"Baudat","year":"2024","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/1538-7445.AM2024-2362","article-title":"Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors","volume":"84","author":"Hart","year":"2024","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1538-7445.AM2024-5083","article-title":"Discovery of an asymmetric IgG-like bispecific ADC targeting EGFR\/HER3","volume":"84","author":"Chen","year":"2024","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1158\/1538-7445.AM2023-6304","article-title":"Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors","volume":"83","author":"Xu","year":"2023","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1158\/1538-7445.AM2023-2967","article-title":"Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_130","first-page":"Tps507","article-title":"CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC\/GEJC)","volume":"43","author":"Yelena","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_131","first-page":"e1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"Yamada","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/2159-8290.CD-22-1467","article-title":"Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression","volume":"13","author":"Hsu","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.05.014","article-title":"PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer","volume":"458","author":"Kedward","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: Current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e431766","DOI":"10.1200\/EDBK_431766","article-title":"Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates","volume":"44","author":"Ascione","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Jang, J.Y., Kim, D., Lee, N.K., Im, E., and Kim, N.D. (2025). Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1081.v1"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-09-2084","article-title":"Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?","volume":"16","author":"Finn","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41523-025-00743-w","article-title":"Novel treatment approaches utilizing antibody-drug conjugates in breast cancer","volume":"11","author":"Davis","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Afzal, M.Z., and Vahdat, L.T. (2024). Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070719"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., and Singhal, S.S. (2024). Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers, 16.","DOI":"10.3390\/cancers16132478"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1535-7163.MCT-24-0078","article-title":"A DXd\/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation","volume":"23","author":"Yue","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Zhao, R.J., and Fan, X.X. (2025). Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041440"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Larrosa, C., Mora, J., and Cheung, N.K. (2023). Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2. Cancers, 15.","DOI":"10.3390\/cancers15143729"},{"key":"ref_148","first-page":"18","article-title":"Novel development strategies and challenges for anti-Her2 antibody-drug conjugates","volume":"5","author":"Zhang","year":"2022","journal-title":"Antib. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","article-title":"A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs","volume":"43","author":"Huang","year":"2025","journal-title":"Investig. New Drugs"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Metrangolo, V., and Engelholm, L.H. (2024). Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers, 16.","DOI":"10.3390\/cancers16020447"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Yao, P., Zhang, Y., Zhang, S., Wei, X., Liu, Y., Du, C., Hu, M., Feng, C., Li, J., and Zhao, F. (2023). Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1039882"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/imcb.70017","article-title":"Highlights of 2024. Broadening anti-cancer immunotherapy modalities with antibody-drug conjugates: Emerging insights from clinical studies","volume":"103","author":"Jose","year":"2025","journal-title":"Immunol. Cell Biol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Zimmerman, B.S., and Esteva, F.J. (2024). Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16040800"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/s12967-024-05453-8","article-title":"Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2\/HER2 homodimers and HER2\/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer","volume":"22","author":"Wei","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e172156","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: Overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","article-title":"Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine\/Threonine-Protein Kinase 2 in HER2+Cell Lines","volume":"34","author":"Chan","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_161","first-page":"18","article-title":"89Zr-immuno-PET for imaging of long circulating drugs and disease targets: Why, how and when to be applied?","volume":"59","author":"Huisman","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Mckertish, C.M., and Kayser, V. (2021). Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080872"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Belluomini, L., Sposito, M., Avancini, A., Insolda, J., Milella, M., Rossi, A., and Pilotto, S. (2023). Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers, 15.","DOI":"10.3390\/cancers15225368"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2767-9764.CRC-22-0137","article-title":"Evaluation of the DLL3-targeting Antibody\u2013Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma","volume":"2","author":"Krytska","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"101801","DOI":"10.1016\/j.tranon.2023.101801","article-title":"B7-H3\/CD276 and small-cell lung cancer: What\u2019s new?","volume":"39","author":"Fabrizio","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41698-025-01131-0","article-title":"The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer","volume":"9","author":"Lin","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00018-024-05556-x","article-title":"The interconnective role of the UPS and autophagy in the quality control of cancer mitochondria","volume":"82","author":"Xu","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2025.43.16_suppl.4519","article-title":"9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-na\u00efve patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): Results from a phase 1b\/2 study","volume":"43","author":"Jiang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2025.43.16_suppl.3001","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations","volume":"43","author":"Yang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2025.43.16_suppl.4017","article-title":"Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2025.43.16_suppl.106","article-title":"Phase 1 study of SHR-1826, a c-MET-directed antibody-drug-conjugate (ADC), in advanced solid tumors","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.2025.43.16_suppl.107","article-title":"Phase 1 trial of SHR-A2102, a nectin-4-directed antibody drug conjugate (ADC), in advanced solid tumors","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e13138","DOI":"10.1200\/JCO.2025.43.16_suppl.e13138","article-title":"First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results","volume":"43","author":"Yao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"100162","DOI":"10.1016\/j.adcanc.2025.100162","article-title":"Roles of the WNT\/\u03b2-catenin signaling pathway in the metastasis and recurrence of NSCLC","volume":"15","author":"Liu","year":"2025","journal-title":"Adv. Cancer Biol.-Metastasis"},{"key":"ref_175","first-page":"34","article-title":"The next frontier in antibody-drug conjugates: Challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_176","first-page":"262","article-title":"Reprogramming the tumor microenvironment: Synergistic mechanisms of antibody\u2013drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:14:45Z","timestamp":1775441685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":176,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073287"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073287","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]}}}